Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company, has named Chris LeMasters as its new chief operating officer and Carlos Sattler MD as its new senior vice president, clinical development, it was reported on Monday.
LeMasters is to lead operations and corporate development, and direct the company's finance and administrative functions. He has also served as chief business officer of Mirati Therapeutics.
Dr Sattler has served in various leadership roles at companies including Halozyme, Sandoz, and Merck. In the new role, Sattler will head the clinical development program for the company's novel, first-in-class antifungal drug candidate, fosmanogepix.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer